Anlotinibplus STUPP: A new hope for glioblastoma patients

A recent study found that adding anlotinib to the standard STUPP regimen for glioblastoma patients could improve outcomes. The trial, involving 33 newly diagnosed patients, reported a median progression-free survival (PFS) of 10.9 months and a median overall survival (OS) of 17.4 months. This promising result suggests a potential new approach for treating this aggressive brain cancer. Further studies are underway to confirm the findings and explore additional therapeutic options.

Glioblastoma multiforme (GBM) is among the most aggressive forms of brain tumors, with few effective treatment options and a bleak prognosis. The current standard of care (SOC), known as the STUPP regimen, includes surgical resection, radiotherapy, and temozolomide chemotherapy. Despite this rigorous approach, median progression-free survival (PFS) and overall survival (OS) are typically low.

A new study (DOI: 10.20892/j.issn.2095-3941.2023.0373) published in Cancer Biology & Medicine in March 2024 suggests that adding anlotinib, a multi-kinase inhibitor, to the STUPP regimen could improve outcomes for glioblastoma patients. Given the high vascularity of glioblastomas, the study assessed the effectiveness of combining anlotinib with the STUPP regimen. The STUPP regimen involves radiation therapy with concurrent and adjuvant temozolomide. Even with this treatment, glioblastoma has a high rate of disease progression within a year.

The trial enrolled 33 patients newly diagnosed with glioblastoma between March 2019 and November 2020. Patients were administered the STUPP regimen in combination with anlotinib at a daily dose of 8 mg, taken continuously for 14 days every 21 days, throughout the duration of their radiotherapy and chemotherapy treatments. Following the completion of chemotherapy, maintenance therapy with anlotinib as a monotherapy was initiated.The study evaluated the efficacy of this combination in extending PFS and OS, showing promising results with a median PFS of 10.9 months and a median OS of 17.4 months. The 12-month PFS and OS rates were 48.5% and 81.8%, respectively, indicating that adding anlotinib might significantly improve outcomes for glioblastoma patients.

Yuanyuan Chen, a co-author of the study, remarked, "Anlotinib plus the STUPP regimen has shown promising anti-tumor activity in glioblastoma while maintaining a tolerable toxicity profile. The results could lead to new treatment strategies for this challenging cancer."

These findings could open new doors for glioblastoma treatment, offering hope to patients with this aggressive cancer. Further studies are planned to explore the full potential of this combination therapy and its effects on survival and quality of life.

###

References

DOI

10.20892/j.issn.2095-3941.2023.0373

Original Source URL

https://doi.org/10.20892/j.issn.2095-3941.2023.0373

Funding information

This work was supported by the National Natural Science Foundation of China (Grant No. 82272744), Natural Science Foundation of Guangdong Province (Grant No. 2022A1515010814), and Sun Yat-sen University Clinical Research 5010 Program (Grant No. 2022008).

About Cancer Biology & Medicine

Cancer Biology & Medicine (CBM) is a peer-reviewed open-access journal sponsored by China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute & Hospital. The journal monthly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal is indexed in SCOPUS, MEDLINE and SCI (IF 5.5, 5 year IF 6.1), with all full texts freely visible to clinicians and researchers all over the world (http://www.ncbi.nlm.nih.gov/pmc/journals/2000/).